Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
REGN
REGN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest REGN ETF News Today | Earnings, Events & Price Alerts
REGN News
Chronic Kidney Disease Market Growth Drivers
11h ago
Newsfilter
EMA Recommends Dupixent Approval for Children with Chronic Urticaria
4d ago
seekingalpha
Dupixent Recommended for EU Approval to Treat Chronic Urticaria in Children
4d ago
Newsfilter
CRISPR Therapeutics Shares Surge on Strong Earnings and Pipeline Growth
5d ago
Benzinga
Regeneron Extends Title Sponsorship of Science Talent Search for Another Decade
5d ago
Globenewswire
Regeneron Extends Title Sponsorship of Science Talent Search for Another Decade
5d ago
Newsfilter
FDA Approves Dupixent for Allergic Fungal Rhinosinusitis Treatment
Feb 25 2026
NASDAQ.COM
Analysis of Regeneron Pharmaceuticals' Future Growth Potential
Feb 25 2026
Fool
Regeneron's Growth Potential Through the Decade
Feb 25 2026
NASDAQ.COM
Regeneron Pharmaceuticals Stock Faces Resistance Amid Mixed Momentum
Feb 24 2026
Benzinga
FDA Approves Dupixent for Allergic Fungal Rhinosinusitis Treatment
Feb 24 2026
seekingalpha
Dupixent Approved for Allergic Fungal Rhinosinusitis Treatment
Feb 24 2026
Newsfilter
FDA Approves Dupixent for Allergic Fungal Rhinosinusitis Treatment
Feb 24 2026
Newsfilter
SANOFI - NEW APPROVAL EXPANDS INDICATIONS FOR SINO-NASAL DISEASES TO INCLUDE AFRS, IN ADDITION TO CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Feb 24 2026
moomoo
SANOFI - DUPIXENT RECEIVES US APPROVAL FOR TREATMENT OF NINE DIFFERENT CONDITIONS ASSOCIATED WITH TYPE 2 INFLAMMATION
Feb 24 2026
moomoo
SANOFI - PHASE 3 TRIAL DEMONSTRATES DUPIXENT EFFICACY IN ALLEVIATING NASAL SIGNS AND SYMPTOMS
Feb 24 2026
moomoo
Show More News
